Related Experiment Video

Updated: Aug 24, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

New molecular targets in melanoma

Keith T Flaherty1

  • 1Instructor of Medicine, Abramson Cancer Center of the University of Pennsylvania, 51 N. 39th Street, MAB 103, Philadelphia, PA 19104, USA. Ktflaherty@aol.com

Current Opinion in Oncology
|April 13, 2004
PubMed

Insights

Metastatic melanoma lacks effective treatments. Current therapies, including vaccines and chemotherapy, show limited success, highlighting the need for novel approaches targeting melanoma

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Metastatic melanoma presents significant therapeutic challenges with limited survival-prolonging options.
  • Existing treatments like peptide/whole-cell vaccines and chemotherapy demonstrate insufficient antitumor activity in advanced disease.
  • Current strategies fail to leverage unique melanoma-specific molecular abnormalities.

Purpose of the Study:

  • To review the current landscape of metastatic melanoma treatment.
  • To highlight the limitations of existing therapeutic modalities.
  • To emphasize the potential of novel therapies targeting molecular pathophysiology.

Main Methods:

  • Literature review of existing treatments for metastatic melanoma.
  • Analysis of clinical trial data for vaccines and chemotherapy.
  • Examination of molecular abnormalities in melanoma.

Main Results:

  • Peptide and whole-cell vaccines have shown limited antitumor effects.
  • Conventional chemotherapeutic agents exhibit restricted efficacy.
  • No current regimen consistently prolongs survival for unresectable metastatic melanoma.

Conclusions:

  • Metastatic melanoma treatment remains an unmet medical need.
  • Novel therapeutic strategies targeting molecular pathways are crucial.
  • Targeted therapies offer hope for improved patient outcomes in metastatic melanoma.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...